Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations

Abstract Immune checkpoint inhibitors (ICIs) are most commonly used for melanoma and non-small cell lung cancer (NSCLC) patients. FAT atypical cadherin 1 (FAT1), which frequently mutates in melanoma and NSCLC. In this study, we aim to investigate the association of FAT1 mutations with ICI response a...

Full description

Bibliographic Details
Main Authors: Wenjing Zhang, Yunfeng Tang, Yuxian Guo, Yujia Kong, Fuyan Shi, Chao Sheng, Suzhen Wang, Qinghua Wang
Format: Article
Language:English
Published: Nature Portfolio 2022-06-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-022-00292-6

Internet

https://doi.org/10.1038/s41698-022-00292-6

Similar Items